🟠 Moderate Evidence
A case of subacute Bartonella quintana bacteremia has been documented in a patient receiving immunomodulatory therapy, highlighting an emerging diagnostic challenge in modern clinical practice. The infection was identified by researchers at the University of Jena in a study published in the International Journal of Infectious Diseases (September 2026), authored by Dr. Sascha D. Grossmann and colleagues. The case underscores how conventional immunosuppressive treatments may create conditions favoring opportunistic bacterial infections previously considered rare in developed healthcare settings.
Key takeaways
- Bartonella quintana bacteremia can develop during immunomodulatory therapy, presenting diagnostic delays in routine clinical care
- Culture-independent molecular diagnostic methods (PCR) may be essential for rapid identification in this high-risk population
- Clinicians prescribing immunosuppressive agents should maintain heightened surveillance for atypical infections
Study at a Glance
| Source | International Journal of Infectious Diseases |
| Study type | Clinical case report |
| Patient population | Adult on immunomodulatory therapy |
| Infection | Subacute Bartonella quintana bacteremia |
| Country | Germany |
Immunocompromised States and Opportunistic Infections
Relative risk of selected bacterial infections in patients on immunomodulatory therapies versus immunocompetent populations
Source: International Journal of Infectious Diseases, September 2026 | Georgian Medical Journal News
Immunomodulation as a Risk Factor for Rare Infections
Immunomodulatory therapies—including biologic agents, corticosteroids, and targeted synthetic disease-modifying antirheumatic drugs (bDMARDs)—have transformed the treatment landscape for autoimmune and inflammatory conditions. However, as documented by Dr. Grossmann and colleagues at the University of Jena, these therapeutic advances carry a countervailing cost: increased susceptibility to opportunistic pathogens that rarely cause infection in immunocompetent individuals.
Bartonella quintana, a gram-negative coccobacillus historically associated with trench fever in military populations and more recently recognized in homeless and immunocompromised cohorts, represents an example of this emerging risk. The bacterium is transmitted primarily by the human body louse (Pediculus humanus humanus) and typically causes self-limited disease in healthy hosts but can progress to life-threatening endocarditis or persistent bacteremia in immunosuppressed patients. The case documented in the International Journal of Infectious Diseases indicates that clinicians must expand their differential diagnostic reasoning when fever, malaise, or constitutional symptoms develop in patients receiving modern immunomodulatory therapies.
Diagnostic Challenges in Molecular and Cultural Methods
A critical barrier to rapid diagnosis of Bartonella bacteremia is the organism’s fastidious nature and slow growth in culture media, often requiring weeks for positive identification. The Jena team’s case report, led by Dr. Grossmann, emphasizes that conventional blood cultures may yield negative or delayed results, particularly in patients presenting with subacute illness. Molecular diagnostic techniques, specifically polymerase chain reaction (PCR) targeting Bartonella-specific genes, have substantially improved diagnostic sensitivity and turnaround time.
This diagnostic vulnerability has direct implications for patient outcomes in clinical practice. Delayed recognition of Bartonella bacteremia can result in prolonged empiric broad-spectrum antibiotic therapy, unnecessary procedures, and in severe cases, disease progression to infective endocarditis. The case presented by the German research team underscores the value of maintaining a high index of clinical suspicion and advocating for molecular confirmation when standard culture methods fail to identify a causative organism in febrile immunocompromised patients.
Subacute bacteremia caused by Bartonella quintana should be included in the differential diagnosis of fever in patients receiving immunomodulatory therapy, particularly when conventional blood cultures remain negative and molecular diagnostics are available.
— Dr. Sascha D. Grossmann, University of Jena (International Journal of Infectious Diseases, September 2026)
Clinical Implications for Prescribing Practitioners
The emergence of Bartonella bacteremia in this clinical context raises several evidence-based questions for healthcare systems. First, should routine screening protocols for occult Bartonella infection be implemented prior to initiating immunomodulatory therapy in high-risk populations (e.g., homeless individuals, those with poor hygiene environments)? Second, are current infectious disease surveillance networks adequately equipped to detect and report such cases, enabling epidemiological trend analysis? The case documented at the University of Jena, published in the International Journal of Infectious Diseases, contributes to emerging evidence that infection control protocols and patient education regarding louse prevention may warrant integration into pretreatment counseling.
Additionally, the German team’s work reinforces recommendations from pharmacy and prescribing guidelines that clinicians maintain awareness of pathogenic shifts in immunocompromised populations. Educational initiatives targeting primary care and specialist practitioners on the recognition and diagnostic approach to fever in immunosuppressed patients may reduce diagnostic delays and improve clinical outcomes.
What this means
Frequently asked questions
What is Bartonella quintana and how is it transmitted?
Bartonella quintana is a gram-negative bacterium historically associated with trench fever and now recognized in homeless and immunocompromised populations. According to the case report from the University of Jena in the International Journal of Infectious Diseases, the organism is transmitted primarily by the human body louse and can cause persistent bacteremia in patients with impaired immune function.
Why is diagnosing Bartonella bacteremia difficult?
The organism is fastidious and grows slowly in culture media, often requiring weeks for identification. Conventional blood cultures may yield negative results even when the infection is present. Molecular diagnostic techniques such as PCR provide faster and more reliable identification, as emphasized in the German research team’s case analysis.
Should I be screened for Bartonella before starting immunomodulatory therapy?
Current clinical guidelines do not universally recommend pre-treatment screening for Bartonella in all patients. However, individuals in high-risk environments (homelessness, overcrowded housing, poor hygiene conditions) and those with symptoms suggestive of Bartonella infection should discuss screening options with their healthcare provider prior to immunosuppressive therapy initiation, particularly given the documented risk illustrated by the Jena case.
As immunomodulatory therapies continue to expand in scope and patient population, clinicians and public health systems must evolve their approach to infection surveillance and diagnosis. The case documented by Dr. Grossmann and colleagues at the University of Jena exemplifies the need for heightened clinical vigilance, access to rapid molecular diagnostics, and systematic reporting of rare infections in immunocompromised cohorts. Future epidemiological studies examining the incidence and clinical outcomes of Bartonella bacteremia in patients on contemporary immunosuppressive agents will inform risk stratification and preventive strategies.
Source: Subacute Bartonella quintana bacteremia following immunomodulatory therapy: a diagnostic challenge, International Journal of Infectious Diseases, September 2026
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
